EVOQ

Evoq Remedies financials

Market cap
₹8 Cr

Quarterly results

Q4 FY26: revenue down 100.0%, net profit down 176.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY23Q4 FY23Q2 FY24Q4 FY24Q2 FY25Q4 FY25Q2 FY26Q4 FY26
Revenue16 5 4 0 0 −100%12 +156%26 +554%0 −100%
EBITDA0 -4 0 -2 -2 −626%-1 +85%-1 −1457%-0 +71%
Net profit0 1 0 0 -2 −623%2 +31%0 +0%-0 −176%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −60.1% 1Y

₹2.00₹3.00₹4.00₹5.00₹6.00Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹3.86 on 9 Sept 2025 → ₹1.54. High ₹5.99 (23 Oct 2025), low ₹1.54 (10 Sept 2026).

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹0 Cr₹14 Cr₹14 Cr₹14 Cr₹25 Cr₹25 Cr
Reserves₹1 Cr₹10 Cr₹11 Cr₹12 Cr₹20 Cr₹19 Cr
Borrowings₹0 Cr₹8 Cr₹10 Cr₹4 Cr₹0 Cr₹0 Cr
Other liabilities₹7 Cr₹2 Cr₹1 Cr₹7 Cr₹8 Cr₹8 Cr
Total liabilities₹8 Cr₹33 Cr₹35 Cr₹37 Cr₹52 Cr₹52 Cr
Fixed assets₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹8 Cr₹33 Cr₹35 Cr₹37 Cr₹52 Cr₹52 Cr
Total assets₹8 Cr₹33 Cr₹35 Cr₹37 Cr₹52 Cr₹52 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Mar 2026

Since Mar 2025, the public added +11.20 pp while promoters trimmed −11.19 pp. The shareholder count shrank 4% to 1,655.

Promoters
0.0%
Public
100.0%

Since Mar 2025

  • Public +11.20 pp
  • Promoters −11.19 pp

How it drifted, 10 quarters

Over this window promoters fell from 73.5% to 0.0% — −73.5 pp.

Mar '22Mar '24Mar '26

Ownership split by quarter, oldest first. Mar '22: Promoters 73.5%, Public 26.5%.Sep '22: Promoters 73.5%, Public 26.5%.Mar '23: Promoters 73.5%, Public 26.5%.Sep '23: Promoters 73.5%, Public 26.5%.Mar '24: Promoters 20.5%, Public 79.5%.Jun '24: Promoters 11.2%, Public 88.8%.Sep '24: Promoters 11.2%, Public 88.8%.Mar '25: Promoters 11.2%, Public 88.8%.Sep '25: Promoters 11.2%, Public 88.8%.Mar '26: Promoters 0.0%, Public 100.0%.

Who was buying across the market this quarter →

Who bought this quarter

since Sep 2025

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 2 holders trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Mar 2026 filing

Every holder of Evoq Remedies Limited above SEBI's 1% disclosure line, and what changed since Sep 2025.

HolderStakeChange
Prashant Sevantikar 11.35%unchanged
Dhruv Ganji 11.35%unchanged
Surya Prakash Jethlia 2.62%newly disclosed
Nilesh M Suhagiya 2.09%newly disclosed
Anand Mohan . 1.53%unchanged
Yashiv Holdings Private Limited 1.46%unchanged
Pattabiraman N R 1.40%newly disclosed
Ambalal Karamshibhai Senghani 1.04%newly disclosed
Gayathri Radhakrishnan 1.04%newly disclosed
Bhumishth Narendrabhai Patel 0.01%−5.18 pp
Patel Payal Bhumishth 0.00%−6.02 pp
Sushilabahen Narendrakumar Patel 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Evoq Remedies Limited

Guides on how to read this kind of business and the numbers that matter.